SOURCE: MolecularMD


April 25, 2016 07:35 ET

MolecularMD Has Obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial

PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - April 25, 2016) - MolecularMD Corp., a molecular diagnostics company that accelerates oncology drug development by providing custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, has partnered with Daiichi Sankyo, Inc. on their work in developing oncology compounds. In collaboration with Daiichi Sankyo, MolecularMD has validated a clinical trial assay that will be used to enrich the patient population for a Phase II clinical trial which is commencing in Europe. MolecularMD has completed the CE registration with the European authorities to ensure future access as an assay, which is to be used for patient selection into the trial.

"Identifying the precise subset of patients who may respond to our compound helps to fully assess its potential efficacy and safety profile," said Antoine Yver, MD, MSc, Executive VP and Global Head, Oncology R&D, Daiichi Sankyo.

"MolecularMD is entirely focused on accelerating development of precision oncology medicines. Our work with Daiichi Sankyo demonstrates our ability to support a wide spectrum of clinical and regulatory strategies," stated Dan Snyder, CEO of MolecularMD. "We have a long standing and successful collaboration with their team."

The arrangement with Daiichi Sankyo represents just one of MolecularMD's Master Service Agreements among the top 25 prominent BioPharma companies in the industry.

About MolecularMD

MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation.

Contact Information

  • Media Inquiries:
    Tina Beauchemin
    (617) 575-2824 x613
    Email contact